구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Monoclonal antibody |
Overview Company | Sung-Soo Park |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting FXIIa, garadacimab acts upstream in the kallikrein-kinin pathway |
MoA Biomarker | biomarkers are strong predictors of accelerated monoclonal antibody clearance |
PK/PD Half-life | 47 h |
PK/PD Species | Cynomolgus monkey, Macaque |
PK/PD Animal (cat.) | NHP, Monkey, In vitro |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Cynomolgus monkey, Macaque |
Toxicology Animal (cat.) | NHP, Monkey, In vitro |
Toxicology Major finding | Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection.. Restoring effective antiviral immunity remains a major challenge in HIV infection. Emerging immune checkpoint leukocyte immunoglobulin-like receptor B1 (LILRB1) and LILRB2 have been proposed as therapeutic targets, yet their in vivo function remains undefined due to the lack of cross-reactive blocking an… |
Toxicology CRS | Reported |
Clinical Safety signal | Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection.. Restoring effective antiviral immunity remains a major challenge in HIV infection. Emerging immune checkpoint leukocyte immunoglobulin-like receptor B1 (LILRB1) and LILRB2 have been proposed as therapeutic targets, yet their in vivo function remains undefined due to the lack of cross-reactive blocking an… |
Clinical Selected reported efficacy | ORR 13% |
Clinical Reported ORR | 13% |
Clinical Result source | ClinicalTrials.gov NCT00068341 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00068341 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Monoclonal antibody |
Overview Company | Sung-Soo Park |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting FXIIa, garadacimab acts upstream in the kallikrein-kinin pathway |
MoA Biomarker | biomarkers are strong predictors of accelerated monoclonal antibody clearance |
PK/PD Half-life | 47 h |
PK/PD Species | Cynomolgus monkey, Macaque |
PK/PD Animal (cat.) | NHP, Monkey, In vitro |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Cynomolgus monkey, Macaque |
Toxicology Animal (cat.) | NHP, Monkey, In vitro |
Toxicology Major finding | Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection.. Restoring effective antiviral immunity remains a major challenge in HIV infection. Emerging immune checkpoint leukocyte immunoglobulin-like receptor B1 (LILRB1) and LILRB2 have been proposed as therapeutic targets, yet their in vivo function remains undefined due to the lack of cross-reactive blocking an… |
Toxicology CRS | Reported |
Clinical Safety signal | Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection.. Restoring effective antiviral immunity remains a major challenge in HIV infection. Emerging immune checkpoint leukocyte immunoglobulin-like receptor B1 (LILRB1) and LILRB2 have been proposed as therapeutic targets, yet their in vivo function remains undefined due to the lack of cross-reactive blocking an… |
Clinical Selected reported efficacy | ORR 13% |
Clinical Reported ORR | 13% |
Clinical Result source | ClinicalTrials.gov NCT00068341 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00068341 |
추천 비교
추천 비교